Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information they need to improve patient outcomes. A distinguished editorial board, led by Dr. Leonidas C. Platanias, identifies key areas of major progress and controversy and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in oncology inform and enhance clinical practice by bringing concepts to a clinical level and exploring their everyday impact on patient care.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Editorial Board - p. iii 6. Contributors - p. v 7. Preface - p. xxi 8. SECTION I: SURGICAL ONCOLOGY - p. xxii 9. Contemporary Management of Dermatofibrosarcoma Protuberans - p. 1 10. Management of Locoregional Melanoma - p. 9 11. Current Management of Intraductal Papillary Mucinous Neoplasms - p. 19 12. SECTION II: MEDICAL ONCOLOGY - p. 28 13. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy - p. 29 14. Optimal Front-Line Therapy for Non-Oncogene-Driven Non-Small Cell Lung Cancer - p. 47 15. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance - p. 63 16. SECTION III: GYNECOLOGIC ONCOLOGY - p. 72 17. Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application - p. 73 18. Surgery for Recurrent Ovarian Cancer - p. 83 19. SECTION IV: PEDIATRIC ONCOLOGY - p. 90 20. Big Data in Pediatric Oncology: Hope, Hype, Reality - p. 91 21. SECTION V: NEURO-ONCOLOGY - p. 99 22. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas - p. 101 23. Diagnostic and Theranostic Opportunities in Neuro-Oncology - p. 111 24. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis - p. 125 25. SECTION VI: HEMATOLOGICAL ONCOLOGY - p. 135 26. Management of Relapsed Refractory Large B-Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation - p. 137 27. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching - p. 147 28. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia - p. 161 29. SECTION VII: URO-ONCOLOGY - p. 175 30. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer - p. 177 31. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Patient Selection and Overview of Doublet and Triplet Therapy Data - p. 185 32. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions - p. 199 33. SECTION VIII: GASTROINTESTINAL ONCOLOGY - p. 206 34. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers - p. 207 35. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers - p. 219 36. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma - p. 233 37. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma - p. 247
Advances in Oncology reviews the year’s most important findings and updates within the field in order to provide practicing oncologists with the current clinical information they need to improve patient outcomes. A distinguished editorial board, led by Dr. Leonidas C. Platanias, identifies key areas of major progress and controversy and invites preeminent specialists to contribute original articles devoted to these topics. These insightful overviews in oncology inform and enhance clinical practice by bringing concepts to a clinical level and exploring their everyday impact on patient care.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Editorial Board - p. iii 6. Contributors - p. v 7. Preface - p. xxi 8. SECTION I: SURGICAL ONCOLOGY - p. xxii 9. Contemporary Management of Dermatofibrosarcoma Protuberans - p. 1 10. Management of Locoregional Melanoma - p. 9 11. Current Management of Intraductal Papillary Mucinous Neoplasms - p. 19 12. SECTION II: MEDICAL ONCOLOGY - p. 28 13. Perioperative Strategies in Non-Small Cell Lung Cancer: Immunotherapy and Targeted Therapy - p. 29 14. Optimal Front-Line Therapy for Non-Oncogene-Driven Non-Small Cell Lung Cancer - p. 47 15. Beyond First-Line Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibitors (TKI): Approach to Resistance - p. 63 16. SECTION III: GYNECOLOGIC ONCOLOGY - p. 72 17. Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer: A Review of the Current Evidence and Clinical Application - p. 73 18. Surgery for Recurrent Ovarian Cancer - p. 83 19. SECTION IV: PEDIATRIC ONCOLOGY - p. 90 20. Big Data in Pediatric Oncology: Hope, Hype, Reality - p. 91 21. SECTION V: NEURO-ONCOLOGY - p. 99 22. Imipridones and Dopamine Receptor Antagonism in the Therapeutic Management of Gliomas - p. 101 23. Diagnostic and Theranostic Opportunities in Neuro-Oncology - p. 111 24. Updates on Revised Diagnostic Criteria and Targeted Therapies for Neurofibromatosis - p. 125 25. SECTION VI: HEMATOLOGICAL ONCOLOGY - p. 135 26. Management of Relapsed Refractory Large B-Cell Non-Hodgkin Lymphoma: Chimeric Antigen Receptor T-Cell Therapy versus Autologous Stem Cell Transplantation - p. 137 27. T-cell Acute Lymphoblastic Leukemia: Novel Therapies Worth Watching - p. 147 28. Prognostic Role and Clinical Utility of Measurable Residual Disease in Acute Myeloid Leukemia - p. 161 29. SECTION VII: URO-ONCOLOGY - p. 175 30. Role of Circulating Tumor DNA for Monitoring of Recurrence and Treatment Response in Urothelial Cancer - p. 177 31. Intensification of Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: Patient Selection and Overview of Doublet and Triplet Therapy Data - p. 185 32. Adjuvant Therapy for Muscle-Invasive Urothelial Cancer: Current Evidence and Future Directions - p. 199 33. SECTION VIII: GASTROINTESTINAL ONCOLOGY - p. 206 34. Defining the Role of Neoadjuvant Therapy for Gastroesophageal Cancers - p. 207 35. Current and Emerging Therapeutic Options for Human Epidermal Growth Factor Receptor 2-Expressing Gastroesophageal Cancers - p. 219 36. Contemporary Systemic Therapy Approaches for Unresectable Hepatocellular Carcinoma - p. 233 37. Multidisciplinary Care and Multimodal Treatment Approaches for Unresectable Hepatocellular Carcinoma - p. 247
